Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target.

Literature DB >> 24826844

Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target.

Roger Stupp, Michael Weller.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2014 PMID： 24826844 PMCID： PMC4022233 DOI： 10.1093/neuonc/nou092

Source DB: PubMed Journal: Neuro Oncol ISSN： 1522-8517 Impact factor: 12.300

× No keyword cloud information.

24 in total

1. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.

Authors: Agda K Lucio-Eterovic; Yuji Piao; John F de Groot
Journal: Clin Cancer Res Date: 2009-06-30 Impact factor: 12.531

2. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

Authors: M S Gordon; K Margolin; M Talpaz; G W Sledge; E Holmgren; R Benjamin; S Stalter; S Shak; D Adelman
Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544

3. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245

4. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Authors: Martin Reck; Joachim von Pawel; Petr Zatloukal; Rodryg Ramlau; Vera Gorbounova; Vera Hirsh; Natasha Leighl; Jörg Mezger; Venice Archer; Nicola Moore; Christian Manegold
Journal: J Clin Oncol Date: 2009-02-02 Impact factor: 44.544

5. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245

6. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316

7. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors: Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544

8. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.

Authors: David E Piccioni; Julia Selfridge; Reema R Mody; Reshmi Chowdhury; Sichen Li; Shadi Lalezari; James Wawrzynski; Jennifer Quan; Mira Zurayk; Arthur P Chou; Desiree E Sanchez; Linda M Liau; Benjamin M Ellingson; Whitney B Pope; Phioanh L Nghiemphu; Richard M Green; He-Jing Wang; William H Yong; Robert Elashoff; Timothy F Cloughesy; Albert Lai
Journal: Neuro Oncol Date: 2014-03-13 Impact factor: 12.300

9. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors: Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal: Cancer Cell Date: 2009-03-03 Impact factor: 31.743

10. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors: Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544

7 in total

1. An overview of neuro-oncology research and practice in Iran, three years with the NOSC initiative.

Authors: Peiman Haddad; Sohrab Shazadi; Farhad Samiei; Homayoun Hadizadeh Kharrazi; Morteza Tabatabaeefar; Afshin Rakhsha; Mohammad Faranoosh; Mohammad Torabi-Nami; Ali Dadras; Atieh Liaghi; Leila Nafarieh
Journal: Int J Clin Exp Med Date: 2015-03-15

2. Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab.

Authors: Timo A Auer; Mirjam Renovanz; Federico Marini; Marc A Brockmann; Yasemin Tanyildizi
Journal: J Neurooncol Date: 2017-05-29 Impact factor: 4.130

3. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.

Authors: D H Heiland; W Masalha; P Franco; M R Machein; A Weyerbrock
Journal: J Neurooncol Date: 2015-11-27 Impact factor: 4.130